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Background. CXL-1020 is a novel HNO donor currently in Phase 2 clinical development for treatment of acute decompensated heart failure 
(ADHF). CXL-1020 improves left ventricular (LV) systolic/diastolic function by directly enhancing calcium handling (myofilament sensitivity/SR 
cycling) and decreasing cardiac loads (veno-/arteriodilation). Here, the load-independence of the functional response to CXL-1020 was evaluated 
via LV pressure-volume analyses, and differentiated from the load-dependent hemodynamic profile of sodium nitroprusside (SNP), a pure vasodilator. 
In addition, the independence of CXL-1020 from beta-adrenergic receptor (`-AR) and ACE activity was demonstrated.
Methods. CXL-1020 (30-300 ug/kg/min) and SNP (25 ug/kg/min) were assayed (IV) in pentobarbital-anesthetized rats (n = 40). CXL-1020 
was also evaluated under either concomitant `-AR blockade (metoprolol, 1 mg/kg)/stimulation (dobutamine, 5 ug/kg/min) or ACE-inhibition 
(enalaprilat, 1 mg/kg/hr). Effects on arterial and LV pressures, as well as on cardiac energetics/function were evaluated via LV pressure-volume 
analyses.
Results. The unloading effects of CXL-1020 (100 ug/kg/min) were similar to those of SNP; CXL-1020 decreased mean arterial pressure (-27±2% 
vs SNP: -32±3%) and increased stroke volume (17±9% vs SNP: 15±9%) without increasing heart rate. However, unlike SNP, CXL-1020 also load-
independently increased inotropy and lusitropy (both P<0.05). These functional effects of CXL-1020 were dose-dependent, and independent of `-AR 
function. Efficacy of CXL-1020 was not altered by ACE inhibition. Compared to dobutamine (matched inotropy), CXL-1020 reduced after-load, stroke 
work, and energetic demand (all P<0.05).
Conclusions. Treatment with CXL-1020 decreased myocardial loading/demand; however CXL-1020 also improved LV systolic/diastolic function in 
a load-independent manner. LV pressure-volume analyses showed CXL-1020 to be mechanistically distinct from nitrovasodilators. The effects of CXL-
1020 were independent of `-AR or angiotensin pathways, and energetically more favorable than dobutamine. Thus, CXL-1020 may be useful in the 
treatment of patients suffering from ADHF.
